-
2024-516612-16-00
4
2020-06-17
gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET)
-
2023-505901-17-00
5
2020-04-24
Acute Myeloid Leukemia (LMA) with FLT3 mutation
-
2023-509699-41-00
9
2019-11-22
Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors
-
2023-510516-39-00
4
2019-10-30
Acute B-cell Lymphoblastic Leukemia with minimal residual positive dis
-
2023-507689-26-00
5
2019-10-07
Histologically or cytologically confirmed Locoregional Hepatocellular
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-518901-16-00
4
2019-07-29
RIS (Radiologically Isolated Syndrome)
-
2024-515690-10-00
9
2019-05-10
Follicular B-cell non-Hodgkin's lymphoma
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2023-508128-37-00
5
2017-07-19
All patients who have been treated with Novartis or Penn CAR T-cell th
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-516078-31-00
10
2015-05-05
Recurrent and Primary Refractory Ewing Sarcoma
-
2025-521067-13-00
5
2026-04-24
Atherosclerotic Cardiovascular Disease (ASCVD)
-
2024-515438-33-00
5
2026-01-12
Alopecia areata
-
2024-517308-13-00
6
2025-12-10
Gram-negative bacteraemia
-
2024-519530-24-00
5
2025-10-31
Overweight and obesity
-
2025-520809-12-00
10
2025-10-16
Diabetic Macular Edema
-
2024-512914-16-00
5
2025-09-12
Relapsing-remitting Multiple Sclerosis
-
2024-516473-72-00
5
2025-07-31
Multifocal Motor Neuropathy
-
2024-519773-19-00
5
2025-07-31
Gastroesophageal Junction Adenocarcinoma
-
2024-518998-33-00
5
2025-07-23
Ulcerative Colitis
-
2024-518687-12-00
4
2025-06-19
Pulmonary Arterial Hypertension (PAH)
-
2024-515523-11-00
5
2025-06-09
Chronic Weight Management